Hearts & Minds Blog

A Closer Look – June 2018

Tim Mayleben

President and Chief Executive Officer

As we approach the halfway point in 2018, our Lipid Management Team remains confident and encouraged by the consistently positive… more

Key Insights from March 2018 ACC: CLEAR Outcomes Looking Even CLEARer After ODYSSEY – Updated ICER Cost-Effectiveness Analysis A Win for Patients and for the Bempedoic Acid Franchise

Tim Mayleben

President and Chief Executive Officer

Our Lipid Management Team attended the 67th Annual Scientific Session of the American College of Cardiology (ACC) in Orlando this… more

Help with Understanding Liver Function Test Increases: From the Lipid Management Team

Tim Mayleben

President and Chief Executive Officer

We recently announced positive results from our first pivotal phase 3 study (Study 4 or the 048 study) of bempedoic… more

The History of LDL-Cholesterol with Dr. Antonio Gotto | Beyond Statins: The Future of Cholesterol Lowering Treatments

Tim Mayleben

President and Chief Executive Officer

Antonio M. Gotto, Jr., MD, DPhil

Dean Emeritus, Weill Cornell Medicine, and Provost for Medical Affairs Emeritus, Cornell University

In Part I and Part II of this series we explored the evolution of LDL-cholesterol: from the early days of… more

Reflecting on a Focused 2017 and Looking Ahead to a Transformational 2018

Tim Mayleben

President and Chief Executive Officer

The past year was marked by tremendous progress for our bempedoic acid-based franchise – perhaps most importantly the achievement of… more